Dyslipidemia and cadiovascular risk in HIV positive pacients on antiretroviral therapyin the western region of Santa Catarina
Introduction: antiretroviral therapy is the key to treat individuals with human immunodeficiency virus, whose efficiency has enabled an increase in life expectancy. Despite this remarkable achievement, antiretroviral therapy is not free of side effects. Among them dyslipidemia represents a striking...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2012 |
| País: | Brasil |
| Institución: | Sociedade Brasileira de Doenças Sexualmente Transmissíveis |
| Repositorio: | DST (Niterói. Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.bjstd.org:article/1081 |
| Acceso en línea: | https://www.bjstd.org/revista/article/view/1081 |
| Access Level: | acceso abierto |
| Palabra clave: | antirretrovirais HIV dislipidemia risco cardiovascular DST antirretrovirals dyslipidemia cardiovascular risk STD |
| Sumario: | Introduction: antiretroviral therapy is the key to treat individuals with human immunodeficiency virus, whose efficiency has enabled an increase in life expectancy. Despite this remarkable achievement, antiretroviral therapy is not free of side effects. Among them dyslipidemia represents a striking role due to its high prevalence and negative effects on quality of life. Objective: to characterize the lipid profile and cardiovascular risk in patients with human immunodeficiency virus who undergo therapy in western Santa Catarina. Methods: cross-sectional quantitative, using medical records of patients enrolled at Hospital Dia until January 2010. Statistical analysis with: T-Student, Chi-square and one-way ANOVA. Results: study population was 113 patients from whom 64.6% had dyslipidemia, the most frequent being the low level of high density lipoprotein (24.8%). Comparing the lipid profile before and after the use of therapy, there was a reduction in the number of dyslipidemias, but these have suffered a worsening (p < 0.05). The combination of Reverse Transcriptase Inhibitors (RTIs) with protease inhibitors (PI) was more related to the development of dyslipidemia (RR = 1.54) and was predominantly low cardiovascular risk. Conclusion: as expected, antiretroviral therapy, primarily through the use of RTIs-PI, was responsible for aggravating the lipid profile of their users that have already had dyslipidemia. However, in this study there was no increase in the absolute number of patients with dyslipidemia and overall cardiovascular risk was low. |
|---|